Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis

Lyme disease Slovenia United States bacteria cytokines genetics immune response inflammation meningitis/encephalitis meningoradiculoneuritis neuroborreliosis peripheral facial palsy polymorphism vector-borne infections

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
04 2022
Historique:
entrez: 23 3 2022
pubmed: 24 3 2022
medline: 2 4 2022
Statut: ppublish

Résumé

Lyme neuroborreliosis (LNB) in Europe may manifest with painful meningoradiculoneuritis (also known as Bannwarth syndrome) or lymphocytic meningitis with or without cranial neuritis (peripheral facial palsy). We assessed host immune responses and the prevalence of TLR1 (toll-like receptor 1)-1805GG polymorphism to gain insights into the pathophysiology of these conditions. Regardless of LNB manifestation, most mediators associated with innate and adaptive immune responses were concentrated in cerebrospinal fluid; serum levels were unremarkable. When stratified by specific clinical manifestation, patients with meningoradiculoneuritis had higher levels of B-cell chemoattractants CXC motif chemokine ligand (CXCL) 12 and CXCL13 and T-cell-associated mediators CXCL9, CXCL10, and interleukin 17, compared with those without radicular pain. Moreover, these patients had a higher frequency of TLR1-1805GG polymorphism and more constitutional symptoms. These findings demonstrate that meningoradiculoneuritis is a distinct clinical entity with unique immune and genetic pathophysiology, providing new considerations for the study of LNB and borrelial meningoradiculitis.

Identifiants

pubmed: 35318928
doi: 10.3201/eid2804.211831
pmc: PMC8962912
doi:

Substances chimiques

Chemokines 0
Cytokines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAMS NIH HHS
ID : K01 AR062098
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI144916
Pays : United States

Références

Clin Sci (Lond). 2008 Mar;114(5):347-60
pubmed: 18230059
Clin Microbiol Infect. 2011 Jan;17(1):69-79
pubmed: 20132258
Clin Infect Dis. 2013 Aug;57(4):501-9
pubmed: 23667259
J Neurol Sci. 2001 Mar 1;184(2):101-22
pubmed: 11239944
J Neurol. 2008 May;255(5):782
pubmed: 27517589
Clin Infect Dis. 2021 May 18;72(10):1719-1726
pubmed: 32221538
Wien Klin Wochenschr. 2002 Jul 31;114(13-14):544-50
pubmed: 12422599
N Engl J Med. 1990 Jul 26;323(4):219-23
pubmed: 2078208
J Neuroinflammation. 2011 Apr 20;8:36
pubmed: 21507218
FEMS Microbiol Rev. 2018 May 1;42(3):233-258
pubmed: 29893904
Semin Arthritis Rheum. 2019 Jun;48(6):1105-1112
pubmed: 30344080
Nat Rev Dis Primers. 2016 Dec 15;2:16090
pubmed: 27976670
Arthritis Rheum. 2012 May;64(5):1311-5
pubmed: 22246662
Res Microbiol. 2008 Jul-Aug;159(6):441-8
pubmed: 18586084
Clin Microbiol Infect. 2018 Dec;24(12):1234-1240
pubmed: 29674128
PLoS One. 2011;6(10):e25998
pubmed: 21998742
Ticks Tick Borne Dis. 2020 May;11(3):101390
pubmed: 32019724
J Neuroinflammation. 2014 Jun 11;11:103
pubmed: 24920219
Arthritis Rheum. 2012 May;64(5):1497-507
pubmed: 22246581
J Exp Med. 2006 Apr 17;203(4):961-71
pubmed: 16585267
APMIS. 2016 Nov;124(11):985-990
pubmed: 27651242
J Neuroinflammation. 2017 Feb 1;14(1):27
pubmed: 28148307
Eur J Neurol. 2010 Jan;17(1):8-16, e1-4
pubmed: 19930447
Emerg Infect Dis. 2016 May;22(5):818-27
pubmed: 27088349
J Infect. 2011 Feb;62(2):149-58
pubmed: 21087629
Clin Vaccine Immunol. 2013 Oct;20(10):1578-84
pubmed: 23945160
BMC Infect Dis. 2012 Dec 10;12:344
pubmed: 23228054
Nat Rev Rheumatol. 2021 Aug;17(8):449-461
pubmed: 34226730
Clin Infect Dis. 2018 Jun 18;67(1):80-88
pubmed: 29340592
Ticks Tick Borne Dis. 2018 Jul;9(5):1137-1142
pubmed: 29705691
Clin Infect Dis. 2021 May 18;72(10):1727-1729
pubmed: 32221531
Clin Infect Dis. 2016 Aug 1;63(3):346-53
pubmed: 27161773
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2221-2229
pubmed: 28730535
J Immunol. 2007 Jun 15;178(12):7520-4
pubmed: 17548585
Lancet. 2012 Feb 4;379(9814):461-73
pubmed: 21903253
Int J Syst Bacteriol. 1994 Oct;44(4):743-52
pubmed: 7981102
Eur J Immunol. 2007 Aug;37(8):2280-9
pubmed: 17595679

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH